[go: up one dir, main page]

ES2114289T3 - Aminoalcanimidazoles y -triazoles acilados. - Google Patents

Aminoalcanimidazoles y -triazoles acilados.

Info

Publication number
ES2114289T3
ES2114289T3 ES95810325T ES95810325T ES2114289T3 ES 2114289 T3 ES2114289 T3 ES 2114289T3 ES 95810325 T ES95810325 T ES 95810325T ES 95810325 T ES95810325 T ES 95810325T ES 2114289 T3 ES2114289 T3 ES 2114289T3
Authority
ES
Spain
Prior art keywords
aminoalcanimidazoles
acilated
triazoles
compounds
hydroxivitamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95810325T
Other languages
English (en)
Inventor
Ingeborg Dr Schuster
Helmut Egger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG, Novartis AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2114289T3 publication Critical patent/ES2114289T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Lubricants (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA INVENCION SE REFIERE A COMPUESTOS DE AZOL DE LA FORMULA (I) EN LA QUE LOS SUSTITUYENTES TIENEN DIFERENTES SIGNIFICADOS, EN FORMA LIBRE O EN FORMA DE SAL. PUEDEN PREPARARSE, POR EJEMPLO, MEDIANTE ACILACION O, MEDIANTE APERTURA DEL ANILLO DE AZIRIDINA O DE OXAZOLA. LOS COMPUESTOS PUEDEN UTILIZARSE COMO PRODUCTOS FARMACEUTICOS, ESPECIALMENTE COMO INHIBIDORES SELECTIVOS DE HIDROXILASAS DE 25-HIDROXIVITAMINA D3 EN EL TRATAMIENTO DE ENFERMEDADES DE PROLIFERACION Y DIFERENCIACION EN TEJIDOS SENSIBLES A LA VITAMINA D.
ES95810325T 1994-05-18 1995-05-16 Aminoalcanimidazoles y -triazoles acilados. Expired - Lifetime ES2114289T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9409882A GB9409882D0 (en) 1994-05-18 1994-05-18 Organic compounds

Publications (1)

Publication Number Publication Date
ES2114289T3 true ES2114289T3 (es) 1998-05-16

Family

ID=10755289

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95810325T Expired - Lifetime ES2114289T3 (es) 1994-05-18 1995-05-16 Aminoalcanimidazoles y -triazoles acilados.

Country Status (30)

Country Link
US (1) US5622982A (es)
EP (1) EP0683156B1 (es)
JP (1) JP2912566B2 (es)
KR (1) KR100371465B1 (es)
CN (1) CN1060163C (es)
AT (1) ATE164576T1 (es)
AU (1) AU696880B2 (es)
BR (1) BR9502062A (es)
CA (1) CA2149459C (es)
CO (1) CO4290423A1 (es)
CZ (1) CZ285385B6 (es)
DE (1) DE69501915T2 (es)
DK (1) DK0683156T3 (es)
ES (1) ES2114289T3 (es)
FI (1) FI112364B (es)
GB (1) GB9409882D0 (es)
GR (1) GR3026505T3 (es)
HK (1) HK1008743A1 (es)
HU (1) HUT72063A (es)
IL (1) IL113743A (es)
MY (1) MY135559A (es)
NO (1) NO304738B1 (es)
NZ (1) NZ272129A (es)
PE (1) PE14896A1 (es)
PH (1) PH31510A (es)
RU (1) RU2152933C2 (es)
SI (1) SI0683156T1 (es)
SK (1) SK280326B6 (es)
TW (1) TW351718B (es)
ZA (1) ZA954074B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0708771T3 (da) * 1993-07-15 1999-06-21 Pfizer Benzyloxyquinuclidiner som substans P antagonister
WO1997018817A1 (fr) * 1995-11-20 1997-05-29 Kiyoshi Kita Preparation externe contenant de la vitamine d ou de la vitamine k
AU2792997A (en) * 1997-05-26 1998-12-30 New Vision Co., Ltd. Medicinal compositions for topical administration containing vitamin d and vitamin k
US6034251A (en) * 1997-11-07 2000-03-07 Schering Corporation Phenyl-alkyl-imidazoles
TW575562B (en) * 1998-02-19 2004-02-11 Agrevo Uk Ltd Fungicides
IL129596A (en) * 1998-05-08 2003-10-31 Dow Agrosciences Llc Preparation of 2-substituted pyridines
GB0029524D0 (en) * 2000-12-04 2001-01-17 Univ Sheffield Disease treatment
GB0128415D0 (en) * 2001-11-27 2002-01-16 Univ Sheffield Medicaments
US7429604B2 (en) * 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2006036892A2 (en) * 2004-09-24 2006-04-06 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
CN104530038A (zh) * 2014-12-10 2015-04-22 沈阳药科大学 酰胺咪唑类衍生物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2041771C3 (de) * 1970-08-22 1979-07-26 Bayer Ag, 5090 Leverkusen derivate
US4191767A (en) * 1977-01-07 1980-03-04 Westwood Pharmaceuticals, Inc. Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines
CH655103A5 (de) * 1983-03-11 1986-03-27 Sandoz Ag Azolderivate, verfahren zu ihrer herstellung und ihre verwendung.
CH677925A5 (es) * 1986-12-03 1991-07-15 Sandoz Ag

Also Published As

Publication number Publication date
EP0683156B1 (en) 1998-04-01
PE14896A1 (es) 1996-05-09
ATE164576T1 (de) 1998-04-15
FI112364B (fi) 2003-11-28
FI952383A0 (fi) 1995-05-16
US5622982A (en) 1997-04-22
CA2149459A1 (en) 1995-11-19
ZA954074B (en) 1996-11-18
PH31510A (en) 1998-11-03
SK280326B6 (sk) 1999-11-08
TW351718B (en) 1999-02-01
BR9502062A (pt) 1996-04-30
DE69501915T2 (de) 1998-08-27
CZ126595A3 (en) 1995-11-15
DE69501915D1 (de) 1998-05-07
KR100371465B1 (ko) 2003-03-19
SK63595A3 (en) 1995-12-06
KR950032147A (ko) 1995-12-20
CA2149459C (en) 2006-09-19
GB9409882D0 (en) 1994-07-06
AU2008995A (en) 1995-11-23
IL113743A0 (en) 1995-08-31
RU2152933C2 (ru) 2000-07-20
CZ285385B6 (cs) 1999-07-14
JPH0853422A (ja) 1996-02-27
MY135559A (en) 2008-05-30
FI952383L (fi) 1995-11-19
HUT72063A (en) 1996-03-28
NO951944D0 (no) 1995-05-16
EP0683156A1 (en) 1995-11-22
NO304738B1 (no) 1999-02-08
CN1120039A (zh) 1996-04-10
HU9501451D0 (en) 1995-06-28
IL113743A (en) 1999-08-17
AU696880B2 (en) 1998-09-24
JP2912566B2 (ja) 1999-06-28
NO951944L (no) 1995-11-20
GR3026505T3 (en) 1998-07-31
CO4290423A1 (es) 1996-04-17
HK1008743A1 (en) 1999-05-14
RU95107652A (ru) 1997-03-20
CN1060163C (zh) 2001-01-03
NZ272129A (en) 1996-05-28
DK0683156T3 (da) 1998-10-19
SI0683156T1 (en) 1998-06-30

Similar Documents

Publication Publication Date Title
AR021844A1 (es) Derivados de propanolamina aril-sustituidos, procedimientos para su preparacion, medicamentos que contienen estos compuestos y su utilizacion
CO4290424A1 (es) Pirazolopiridinas, pirrolopiridinas, composiciones farmaceu- ticas que las contienen y procedimientos para su administra- cion como antagonista del factor de liberacion de cortico- tropina
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
UY23835A1 (es) Procedimiento para la preparacion de compuesto de acilo
AR025444A1 (es) Derivados de sulfonil-carboxamida, procedimientos para su preparacion y su utilizacion como medicamentos
ES2196377T3 (es) Derivados de naftiridina.
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
ES2146300T3 (es) Utilizacion de composiciones antihelminticas para el tratamiento de infecciones causadas por anoplocephala perfoliata en equidos.
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
ES2136037A1 (es) Inhibidores de sulfamida-metaloproteasa
ES2115237T3 (es) Fenil heterociclos como inhibidores de la ciclooxigenasa-2.
ES2174465T3 (es) Compuestos triazol y su utilizacion como ligandos de dopamina-d.
UY26839A1 (es) Productos de derivados de la 4 - fenil - piridina
PA8442001A1 (es) Derivados de pirimidina biciclica condensada
UY27981A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
UY27350A1 (es) Azaindoles
MX9304015A (es) Antagonistas de oxitoxina.
ES2114289T3 (es) Aminoalcanimidazoles y -triazoles acilados.
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
PA8489501A1 (es) Antibioticos cetolidos
ES2129485T3 (es) Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
ES2093440T3 (es) Derivados en la serie de la vitamina d con modificaciones en la posicion 20, procedimiento para su preparacion, productos intermedios para este procedimiento, preparados farmaceuticos que contienen estos derivados asi como su utilizacion para la preparacion de medicamentos.
AR021843A1 (es) Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion.
ES2174921T3 (es) Inhibidores de la proteasa del vih.
GT200500020A (es) Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 683156

Country of ref document: ES